2023³â ´ëÇÑÀ̽ÄÇÐȸ Á¦19Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-03-18
±³À°ÀÏÀÚ : 2023-03-18
±³À°Àå¼Ò : ´ëÀüÄÁº¥¼Ç¼¾ÅÍ(DCC)
±³À°ÁÖÁ¦ : 2023³â ´ëÇÑÀ̽ÄÇÐȸ Á¦19Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÀ̽ÄÇÐȸ
´ã´çÀÚ : ´ëÇÑÀ̽ÄÇÐȸ
¿¬¶ôó : 02-484-8052
À̸ÞÀÏ : mykst@mykst.org
±³À°Á¾·ù : ³»°ú, ¿Ü°ú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ´ëÀü±¤¿ª½Ã
±³À°½Ã°£ : 19 ½Ã°£ 48ºÐ
¼¼ºÎ¼ö°·á : 160,000¿ø
ºñ°í »çÀüµî·Ï Á¤È¸¿ø: 10¸¸¿ø, ÁØȸ¿ø: 5¸¸¿ø, ºñȸ¿ø: 15¸¸¿ø ÇöÀåµî·Ï Á¤È¸¿ø: 12¸¸¿ø, ÁØȸ¿ø: 6¸¸¿ø, ºñȸ¿ø: 16¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-18 201È£ 08:00~08:30 Vitallink ÇöȲ º¸°í ÀÌ»ï¿(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 08:30~09:00 KODA ÇöȲ º¸°í ¹®Àμº(KODA)
±³À°½Ã°£ 03-18 201È£ 09:00~09:30 KOTRY ÇöȲ º¸°í ±è¸í¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-18 101/102È£ 08:00~08:20 ¼Ò¾Æ ³ú»ç±âÁõÀÚ ºÐ¼®°ú ¼öÇý °á°ú Æò°¡¿¡ ±âÃÊÇÑ Àå±â ºÐ¹è °³¼± ¹æ¾È ÃÖ¿µ·Ï(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 03-18 101/102È£ 08:20~08:40 °£¼¼Æ÷¾Ï ȯÀÚÀÇ »ýü °£ÀÌ½Ä ¼ö¼ú Àü°ú ÈÄÀÇ Ç÷û ³» ¿°Áõ¼º »çÀÌÅäÄ«ÀÎ ¹× ¹ÙÀÌ¿À¸¶Ä¿ ÃøÁ¤-ÇãÇ÷/Àç°ü·ù ¼Õ»ó ¹× °£¼¼Æ÷¾Ï Àç¹ß¿¡ ´ëÇÑ ¿¬°ü¼º ºÐ¼®À» À§ÇÑ ¼±Çà °úÁ¦ À¯Áø¼ö(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 03-18 101/102È£ 08:40~09:00 ½ÅÀåÀÌ½Ä ÈÄ ±â°è ÇнÀÀ» ÀÌ¿ëÇÑ À̽ĽŠ±â´É °¨¼Ò ¿¹Ãø ¸ðµ¨ ¹× À§Çè ÀÎÀÚ ¹ß±¼ ÀÌÀ¯È£(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 03-18 101/102È£ 09:00~09:20 ¿ì¸®³ª¶ó ¼Ò¾Æ °íÇüÀå±âÀÌ½Ä µî·Ï»ç¾÷ °Èñ°æ(¼¿ï´ëº´¿ø)
Åä·Ð 03-18 101/102È£ 09:20~09:30 Discussion ()
±³À°½Ã°£ 03-18 201È£ 09:30~09:45 Pretransplant workup & risk factor evaluation of alcohol relapse ¹ÚÁØ¿ë(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 09:45~10:00 Surgical outcones, living donor & allocation associated delemma ±èÈ¿½Å(Àü³²ÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 10:00~10:15 Ethical delemma cases ±èÇü¼÷(¼¿ï¼º¸ðº´¿ø)
Åä·Ð 03-18 201È£ 10:15~10:30 Panel Discussion ¹ÚÁ¤ºÐ, ±èµ¿½Ä, ±Ç¿µ¶õ, ¹ÚÁØ¿ë, ±èÈ¿½Å, ±èÇü¼÷(KONOS, °í·ÁÀÇ´ë, Àü³²ÀÇ´ë, ¿¬¼¼ÀÇ´ë, Àü³²ÀÇ´ë, ¼¿ï¼º¸ðº´¿ø)
ÈÞ½Ä 03-18 201È£, 101/102È£ 10:30~10:50 Coffee Break ()
±³À°½Ã°£ 03-18 201È£ 10:50~11:05 KT: Long-term outcome after kidney donation in Korea °ÀºÁ¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 11:05~11:20 KT: Policy proposal to improve the outcome of kidney donor ÀåÇý·Ã(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 11:20~11:35 LT: Overview of long-term outcome of living liver donor ÇÑ´ëÈÆ(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 03-18 201È£ 11:35~11:50 LT: Standard guideline for post-donation care in living liver donor ·ùÁ¦È£(ºÎ»êÀÇ´ë)
Åä·Ð 03-18 201È£ 11:50~12:20 Panel Discussion °¸íÁø, Çã±ÔÇÏ, Á¶ÀåÈñ, Á¤µ¿È¯, ¹ÚÇýÀ±, ÃÖ±Ô¼º(º¸°Çº¹ÁöºÎ Ç÷¾×Àå±âÁ¤Ã¥°ú, ¿¬¼¼ÀÇ´ë, °æºÏÀÇ´ë, ¼¿ï¾Æ»êº´¿ø, ¼¿ï´ë, ¼º±Õ°üÀÇ´ë)
½Ä»ç 03-18 12:50~13:50 Luncheon Symposium ()
±³À°½Ã°£ 03-18 201È£ 13:50~14:00 ATG vs. basiliximab: Pro À̱³¿ø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 14:00~14:10 ATG vs. basiliximab: Cons ±ÇÇö¿í(¿ï»êÀÇ´ë)
Åä·Ð 03-18 201È£ 14:10~14:20 Discussion ()
±³À°½Ã°£ 03-18 201È£ 14:20~14:30 Rituximab: necessity, dose, timing: Pro Á¤º´ÇÏ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 14:30~14:40 Rituximab: necessity, dose, timing: Cons ÀÌÁÖÇÑ(¿¬¼¼ÀÇ´ë)
Åä·Ð 03-18 201È£ 14:40~14:50 Discussion ()
±³À°½Ã°£ 03-18 201È£ 14:50~15:00 Early initiation of maintenance treatment: agent, dose, timing: Pro Á¤Ã¶¿õ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 15:00~15:10 Early initiation of maintenance treatment: agent, dose, timing: Cons ±è¿ëö(¼¿ïÀÇ´ë)
Åä·Ð 03-18 201È£ 15:10~15:20 Discussion ()
±³À°½Ã°£ 03-18 101/102È£ 13:50~14:05 Down-staging for advanced HCC in LT - surgeon ¼Û±â¿ø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03-18 101/102È£ 14:05~14:20 Down-staging for advanced HCC in LT - hepatologist À¯¼öÁ¾(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-18 101/102È£ 14:20~14:35 Evolution in biomarkers to assess tumor biology ¹ÚÁØ¿ë(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-18 101/102È£ 14:35~14:50 How to manage post-LT recurrence È«Á¤¿ë(¼º±Õ°üÀÇ´ë)
Åä·Ð 03-18 101/102È£ 14:50~15:20 Discussion ()
±³À°½Ã°£ 03-18 103/104È£ 13:50~14:08 Optimal Donor management protocol ÇöÁØÈ£(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03-18 103/104È£ 14:08~14:26 Organ preservation techniques for remote transplantation including preservation solutions ±èÁؼº(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-18 103/104È£ 14:26~14:44 Marginal donor: expanding donor category ÁÖ¹ÎÈ£(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 03-18 103/104È£ 14:44~15:02 Heart transplantation after the circulatory death: what we need or how to prepare? ÀÌÇØ¿µ(¼¿ïÀÇ´ë)
Åä·Ð 03-18 103/104È£ 14:02~15:20 Panel Discussion À̼±È, Ȳȣ¿µ, Á¶¾çÇö, Á¤Àμ®, ÀÌÁÖÈñ(°è¸íÀÇ´ë, ¼¿ïÀÇ´ë, ¼º±Õ°üÀÇ´ë, Àü³²ÀÇ´ë, ÃæºÏÀÇ´ë)
±³À°½Ã°£ 03-18 105È£ 13:50~13:58 Kidney allograft anti-GBM glomerulonephritis in a patient with Alport syndrome: Case presentation ¼ÛÁ¤ÀÎ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-18 105È£ 13:58~14:06 Kidney allograft anti-GBM glomerulonephritis in a patient with Alport syndrome: Lab/Patho/Infection ¹®°æö(¼¿ïÀÇ´ë)
Åä·Ð 03-18 105È£ 14:06~14:12 Discussion ()
±³À°½Ã°£ 03-18 105È£ 14:12~14:20 Uncovering atypical hemolytic uremic syndrome in a post-transplant end-stage kidney disease patient through CFH-22 deletion identification: Case presentation ÀÌÇÏÀº(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 03-18 105È£ 14:20~14:28 Uncovering atypical hemolytic uremic syndrome in a post-transplant end-stage kidney disease patient through CFH-22 deletion identification: Lab/Patho/Infection ±èÈƼ®(¼¿ï¼º¸ðº´¿ø)
Åä·Ð 03-18 105È£ 14:28~14:34 Discussion ()
±³À°½Ã°£ 03-18 105È£ 14:34~14:42 Malakoplakia after Kidney transplantation: Case presentation ÀÓ½ÂÇõ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-18 105È£ 14:42~14:50 Malakoplakia after Kidney transplantation: Lab/Patho/Infection ÀÓ¹üÁø(¿¬¼¼ÀÇ´ë)
Åä·Ð 03-18 105È£ 14:50~14:56 Discussion ()
±³À°½Ã°£ 03-18 105È£ 14:56~15:04 pulmonary nocardiosis: Case presentation Çã°æ¹Î(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-18 105È£ 15:04~15:12 pulmonary nocardiosis: Lab/Patho/Infection Çã°æ¹Î(¼º±Õ°üÀÇ´ë)
Åä·Ð 03-18 105È£ 15:12~15:18 Discussion ()
±³À°½Ã°£ 03-18 106È£ 13:50~14:20 Àå±âÀÌ½Ä À±¸®¿Í »ý¸í³ª´® ¼Õ¼±¿µ(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 03-18 106È£ 14:20~14:50 Àå±âÀÌ½Ä ÇöÀåÀÇ À±¸®Àû À̽´¿Í ÇöȲ ±èÇü¼÷(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 03-18 106È£ 14:50~15:20 Àå±âÀ̽ÄÄÚµð³×ÀÌÅÍÀÇ Àü¹®°¡·Î¼ À±¸®Àû °¥µî ´ë¾È ¹× ±³À°ÀÇ Çʿ伺 À±Àº°æ(°æÈñ°£È£)
ÈÞ½Ä 03-18 201È£, 101~106È£ 15:20~15:40 Coffee Break ()
±³À°½Ã°£ 03-18 201È£ 15:40~16:10 Tolerization trials ½ÅÈ£½Ä(°í½ÅÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 16:10~16:40 Genomic study Á¤Á¾Ã¶(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-18 201È£ 16:40~17:10 cfDNA, exosome ÀÌ»óÈ£(°æÈñÀÇ´ë)
±³À°½Ã°£ 03-18 101/102È£ 15:40~16:00 Basics in interpretation of LT pathology ±èÁöÈÆ(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 03-18 101/102È£ 16:00~16:20 ACR and CR in LT - pathopysiology and diagnosis Á¤Àº¼º(ÀºÆò¼º¸ð)
±³À°½Ã°£ 03-18 101/102È£ 16:20~16:40 Acute and chronic AMR in LT - pathopysiology and diagnosis ±èÇý·É(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-18 101/102È£ 16:40~17:00 Liquid biopsy in LT pathology ¿ÀÀºÁö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-18 103/104È£ 15:40~15:58 Recent changes in recipient registration and donor matching process ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø)
±³À°½Ã°£ 03-18 103/104È£ 15:58~16:16 Progression in pediatric heart transplantation ÀÌ»óÀ±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-18 103/104È£ 16:16~16:34 Challenges of heart transplantation: cardiac amyloidosis ±è´Ù·¡(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-18 103/104È£ 16:34~16:52 Xenotransplantation À±Á¾Âù(°¡Å縯ÀÇ´ë)
Åä·Ð 03-18 103/104È£ 16:52~17:10 Panel Discussion °ûÀç°Ç, Á¶ÇöÀç, À̼ö¿ë, Àå¿ì¼º, ¿ÀÀç¿ø(¼¿ïÀÇ´ë, ¼¿ïÀÇ´ë, ºÎ»êÀÇ´ë, °è¸íÀÇ´ë, ¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-18 105È£ 15:40~15:58 Induction protocol of Korean lung transplantation ¿©ÇýÁÖ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 03-18 105È£ 15:58~16:16 Maintenance of immune medication ÀÓ¼ºÀ±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-18 105È£ 16:16~16:34 Prophylaxis of infection Àü°æ¸¸(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-18 105È£ 16:34~16:52 PRA, cross matching and desensitization protocol ¿ì¾Æ¶ó(¿¬¼¼ÀÇ´ë)
Åä·Ð 03-18 105È£ 16:52~17:10 Panel Discussion ¹Ú¼ºÈÆ, ¹Ú»ùÀ̳ª, ÇÔ¼®Áø, ¹Ú¹«¼®(ÇѸ²ÀÇ´ë, ¼¿ï´ë, ¾ÆÁÖÀÇ´ë, ¿¬¼¼ÀÇ´ë)